Morgan Stanley
KRTX

Morgan Stanley’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Morgan Stanley’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-312,082
Closed -$98.8M – 8039
2023
Q4 		$98.8M Buy
312,082
+260,397
+504% +$50.6M ﹤0.01% 1738
2023
Q3 		$8.74M Sell
51,685
-52,432
-50% -$9.86M ﹤0.01% 3244
2023
Q2 		$22.6M Buy
104,117
+10,884
+12% +$2.33M ﹤0.01% 2358
2023
Q1 		$16.9M Sell
93,233
-18,970
-17% -$3.63M ﹤0.01% 2603
2022
Q4 		$22M Sell
112,203
-33,941
-23% -$7.28M ﹤0.01% 2241
2022
Q3 		$32.9M Sell
146,144
-6,788
-4% -$1.37M ﹤0.01% 1679
2022
Q2 		$19.3M Buy
152,932
+21,847
+17% +$2.51M ﹤0.01% 2326
2022
Q1 		$16.6M Buy
131,085
+52,114
+66% +$5.87M ﹤0.01% 2322
2021
Q4 		$10.3M Buy
78,971
+29,480
+60% +$3.81M ﹤0.01% 2917
2021
Q3 		$6.05M Sell
49,491
-23,652
-32% -$2.73M ﹤0.01% 3471
2021
Q2 		$8.34M Sell
73,143
-26,212
-26% -$3.06M ﹤0.01% 3203
2021
Q1 		$11.9M Buy
99,355
+86,239
+658% +$9.77M ﹤0.01% 2471
2020
Q4 		$1.33M Buy
13,116
+9,046
+222% +$838K ﹤0.01% 4480
2020
Q3 		$315K Sell
4,070
-4,552
-53% -$388K ﹤0.01% 4878
2020
Q2 		$961K Buy
8,622
+6,660
+339% +$579K ﹤0.01% 4207
2020
Q1 		$141K Sell
1,962
-6,182
-76% -$529K ﹤0.01% 5038
2019
Q4 		$614K Buy
8,144
+6,185
+316% +$271K ﹤0.01% 4818
2019
Q3 		$32K Buy
+1,959
New +$38.1K ﹤0.01% 5879

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Morgan Stanley's KRTX Position: Q1 2024 in Review

Morgan Stanley sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 312,082 shares — an estimated $98.8M sold.

Morgan Stanley first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $98.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Morgan Stanley reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 312,082 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $98.8M.
  • Morgan Stanley first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
  • Morgan Stanley's Karuna Therapeutics, Inc. Common Stock position peaked at $98.8M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.